Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research.

COVID-19 / complications Humans Research Design SARS-CoV-2 Treatment Outcome Post-Acute COVID-19 Syndrome COVID-19 Drug Treatment
Long COVID dyspnoea fatigue post-COVID-19 condition rehabilitation treatment

Journal

Infectious diseases (London, England)
ISSN: 2374-4243
Titre abrégé: Infect Dis (Lond)
Pays: England
ID NLM: 101650235

Informations de publication

Date de publication:
07 2022
Historique:
pubmed: 15 3 2022
medline: 18 5 2022
entrez: 14 3 2022
Statut: ppublish

Résumé

A considerable proportion of individuals report persistent, debilitating and disparate symptoms despite resolution of acute COVID-19 infection (i.e. long COVID). Numerous registered clinical trials investigating treatment of long COVID are expected to be completed in 2021-2022. The aim of this review is to provide a scope of the candidate treatments for long COVID. A synthesis of ongoing long COVID clinical trials can inform methodologic approaches for future studies and identify key research vistas. Scoping searches were conducted on multiple national and international clinical trial registries. Interventional trials testing treatments for long COVID were selected. The search timeline was from database inception to 28 July 2021. This scoping review included 59 clinical trial registration records from 22 countries with a total projected enrolment of 6718. Considerable heterogeneity was exhibited amongst component records with respect to the characterization of long COVID (i.e. name, symptoms- including frequency, intensity, trajectory and duration- mode of ascertainment, and definition of acute phase). In addition, the majority of proposed interventions were non-pharmacological and either targeted multiple long COVID symptoms simultaneously, or focussed on treatment of respiratory/pulmonary sequelae. Multiple interventions targeted inflammation, as well as tissue oxygenation and cellular recovery, and several interventions were repurposed from analogous conditions. The results of this scoping review investigating ongoing clinical trials testing candidate treatments for long COVID suggest that a greater degree of definitional stringency and homogeneity is needed insofar as the characterization of long COVID and inclusion/exclusion criteria.

Sections du résumé

BACKGROUND
A considerable proportion of individuals report persistent, debilitating and disparate symptoms despite resolution of acute COVID-19 infection (i.e. long COVID). Numerous registered clinical trials investigating treatment of long COVID are expected to be completed in 2021-2022. The aim of this review is to provide a scope of the candidate treatments for long COVID. A synthesis of ongoing long COVID clinical trials can inform methodologic approaches for future studies and identify key research vistas.
METHODS
Scoping searches were conducted on multiple national and international clinical trial registries. Interventional trials testing treatments for long COVID were selected. The search timeline was from database inception to 28 July 2021.
RESULTS
This scoping review included 59 clinical trial registration records from 22 countries with a total projected enrolment of 6718. Considerable heterogeneity was exhibited amongst component records with respect to the characterization of long COVID (i.e. name, symptoms- including frequency, intensity, trajectory and duration- mode of ascertainment, and definition of acute phase). In addition, the majority of proposed interventions were non-pharmacological and either targeted multiple long COVID symptoms simultaneously, or focussed on treatment of respiratory/pulmonary sequelae. Multiple interventions targeted inflammation, as well as tissue oxygenation and cellular recovery, and several interventions were repurposed from analogous conditions.
CONCLUSIONS
The results of this scoping review investigating ongoing clinical trials testing candidate treatments for long COVID suggest that a greater degree of definitional stringency and homogeneity is needed insofar as the characterization of long COVID and inclusion/exclusion criteria.

Identifiants

DOI: 10.1080/23744235.2022.2043560 PMID: 35282780 PMC: PMC8935463
pubmed: 35282780
doi: 10.1080/23744235.2022.2043560
pmc: PMC8935463
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

467-477

Auteurs

Felicia Ceban (F)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.
Brain and Cognition Discovery Foundation, Toronto, Canada.
ORCID: 0000-0001-6815-7248

Alexia Leber (A)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.

Muhammad Youshay Jawad (MY)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.

Mathew Yu (M)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.

Leanna M W Lui (LMW)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.

Mehala Subramaniapillai (M)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.
Brain and Cognition Discovery Foundation, Toronto, Canada.

Joshua D Di Vincenzo (JD)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.

Hartej Gill (H)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.

Nelson B Rodrigues (NB)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.

Bing Cao (B)

Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing, PR China.
ORCID: 0000-0001-5963-2676

Yena Lee (Y)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.
Brain and Cognition Discovery Foundation, Toronto, Canada.

Kangguang Lin (K)

Department of Affective Disorders, the Affiliated Brain Hospital of Guangzhou Medical University, (Guangzhou Huiai Hospital), Guangzhou Medical University, Guangzhou, PR China.
Laboratory of Emotion and Cognition, the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou Medical University, Guangzhou, PR China.

Rodrigo B Mansur (RB)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.

Roger Ho (R)

Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore.

Matthew J Burke (MJ)

Department of Psychiatry, University of Toronto, Toronto, Canada.
Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada.
Department of Neurology, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Joshua D Rosenblat (JD)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.

Roger S McIntyre (RS)

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.
Brain and Cognition Discovery Foundation, Toronto, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Registered clinical trials investigating...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Registered clinical trials investigating...
questionsmedicales.fr › Disciplines des sciences naturelles › Science › Recherche › Plan de recherche › Registered clinical trials investigating...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Registered clinical trials investigating...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Registered clinical trials investigating...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Troubles post-infectieux › Syndrome de post-COVID-19 › Registered clinical trials investigating...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitements médicamenteux de la COVID-19 › Registered clinical trials investigating...